



Altimune to Present at Upcoming Investor Conferences

May 16, 2022

GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences in May 2022:

- **H.C. Wainwright Global Investment Conference**

Tuesday, May 24, 2022

7:00 am Eastern Time

The session will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

- **B. Riley Securities Institutional Investor Conference**

Thursday, May 26, 2022

1:00 pm Pacific Time

The session will be an in person fireside chat.

About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Altimune Investor & Media Contact:

Richard Eisenstadt

Chief Financial Officer

Phone: 240-654-1450

reisenstadt@altimmune.com



Source: Altimune, Inc